BioCentury
ARTICLE | Clinical News

Aplidin plitidepsin: Phase III data

April 4, 2016 7:00 AM UTC

Top-line data from the open-label, international Phase III ADMYRE trial in 255 patients with relapsed or relapsed MM after 3-6 prior therapies showed that 5 mg/m 2 IV Aplidin on days 1 and 15 of every 4-week cycle plus dexamethasone met the primary endpoint of improving PFS vs. dexamethasone alone. Specifically, Aplidin plus dexamethasone reduced the risk of disease progression or death by 35% vs. dexamethasone (p=0.0054). ...